HBcrAg等三種血清學標志物水平
與肝內HBV cccDNA水平的相關性
參考文獻： [1]唐紅. HBV 感染 “新型” 生物標志物的 “前世今生”[J]. 臨床肝膽病雜志, 2019, 35(10): 2137-2139. [2]陳恩強, 唐紅. 一種有前途的新型 HBV 血清標志物——HBcrAg[J]. 臨床肝膽病雜志, 2019 (10): 7. [3]Mak L Y, Wong D K H, Cheung K S, et al. hepatitis B core‐related antigen (HB crAg): an emerging marker for chronic hepatitis B virus infection[J]. Alimentary pharmacology & therapeutics, 2018, 47(1): 43-54. [4]Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core‐related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment[J]. Journal of viral hepatitis, 2003, 10(4): 324-330. [5]Chen E Q, Feng S, Wang M L, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J]. Scientific Reports, 2017, 7(1): 1-8. [6]Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication[J]. Antiviral therapy, 2008, 13(1): 57. [7]Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology. 2004;40:727‐737. [8]Caviglia G P, Abate M L, Noviello D, et al. Hepatitis B core‐related antigen kinetics in chronic hepatitis B virus genotype D‐infected patients treated with nucleos (t) ide analogues or pegylated‐interferon‐α[J]. Hepatology Research, 2017, 47(8): 747-754. [9]Kim G A, Lim Y S, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability[J]. Gut, 2014, 63(8): 1325-1332. [10]Hsu Y C, Mo L R, Chang C Y, et al. Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients[J]. Clinical Gastroenterology and Hepatology, 2016, 14(10): 1490-1498. e3. [11]Hsu Y C, Nguyen M H, Mo L R, et al. Combining hepatitis B core‐related and surface antigens at end of nucleos (t) ide analogue treatment to predict off‐therapy relapse risk[J]. Alimentary pharmacology & therapeutics, 2019, 49(1): 107-115. [12]Wong D K H, Seto W K, Cheung K S, et al. Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA[J]. Liver International, 2017, 37(7): 995-1001. [13]Liang L Y, Wong V W S, Toyoda H, et al. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients[J]. Journal of gastroenterology, 2020: 1-10.
聲明：本內容僅針對中國醫療衛生專業人士，旨在向且僅向醫療衛生專業人士提供科學信息，用于個人學習和參考之用。如果您不是醫療衛生專業人士，請勿參與或傳播。
